Narges K Tafreshi
Overview
Explore the profile of Narges K Tafreshi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
460
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tafreshi N, Kil H, Pandya D, Tichacek C, Doligalski M, Budzevich M, et al.
ACS Pharmacol Transl Sci
. 2021 Apr;
4(2):953-965.
PMID: 33860213
Lipophilicity is explored in the biodistribution (BD), pharmacokinetics (PK), radiation dosimetry (RD), and toxicity of an internally administered targeted alpha-particle therapy (TAT) under development for the treatment of metastatic melanoma....
2.
Tafreshi N, Pandya D, Tichacek C, Budzevich M, Wang Z, Reff J, et al.
Eur J Nucl Med Mol Imaging
. 2021 Mar;
48(11):3408-3421.
PMID: 33772332
Purpose: There is significant interest in the development of targeted alpha-particle therapies (TATs) for treatment of solid tumors. The metal chelator-peptide conjugate, DOTA-TATE, loaded with the β-particle emitting radionuclide Lu...
3.
Tichacek C, Tafreshi N, Kil H, Engelman R, Doligalski M, Budzevich M, et al.
Mol Pharm
. 2020 Sep;
17(11):4180-4188.
PMID: 32960613
Targeted α particle therapy (TAT) is ideal for treating disease while minimizing damage to surrounding nontargeted tissues due to short path length and high linear energy transfer (LET). We developed...
4.
Tafreshi N, Morse D, Lee M
World J Clin Oncol
. 2020 May;
11(4):169-179.
PMID: 32355639
Triple-negative breast cancer (TNBC) is defined as a type of breast cancer with lack of expression of estrogen receptor, progesterone receptor and human epidermal growth factor 2 protein. In comparison...
5.
Tafreshi N, Doligalski M, Tichacek C, Pandya D, Budzevich M, El-Haddad G, et al.
Molecules
. 2019 Nov;
24(23).
PMID: 31779154
Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or small molecules that recognize tumor-associated antigens or cell-surface...
6.
Tafreshi N, Tichacek C, Pandya D, Doligalski M, Budzevich M, Kil H, et al.
J Nucl Med
. 2019 Feb;
60(8):1124-1133.
PMID: 30733316
New effective therapies are greatly needed for metastatic uveal melanoma, which has a very poor prognosis with a median survival of less than 1 y. The melanocortin 1 receptor (MC1R)...
7.
Damaghi M, Tafreshi N, Lloyd M, Sprung R, Estrella V, Wojtkowiak J, et al.
Nat Commun
. 2015 Dec;
6:8752.
PMID: 26658462
Early cancers are avascular and hence, profoundly acidic. Pre-malignant cells must adapt to acidosis to thrive in this hostile microenvironment. Here, we investigate MCF-7 cells that are adapted to grow...
8.
Tafreshi N, Lloyd M, Proemsey J, Bui M, Kim J, Gillies R, et al.
Mol Imaging Biol
. 2015 Aug;
18(2):219-31.
PMID: 26276155
Purpose: Hypoxia is commonly observed in regions of primary tumors and metastases, and is associated with resistance to treatment, more aggressive tumor phenotypes and poor prognosis. Reliable and validated imaging...
9.
Luddy K, Robertson-Tessi M, Tafreshi N, Soliman H, Morse D
Front Immunol
. 2014 Nov;
5:429.
PMID: 25368611
Toll-like receptors (TLRs) are expressed by immune cells, intestinal epithelium, and tumor cells. In the homeostatic setting, they help to regulate control over invading pathogens and maintain the epithelial lining...
10.
Tafreshi N, Lloyd M, Bui M, Gillies R, Morse D
Subcell Biochem
. 2013 Oct;
75:221-54.
PMID: 24146382
Carbonic anhydrase IX (CAIX) which is a zinc containing metalloprotein, efficiently catalyzes the reversible hydration of carbon dioxide. It is constitutively up-regulated in several cancer types and has an important...